Skip to content

This is a single center study wherein the efficacy of Sabeet® in cardiovascular and exercise performance will be studied in 20 adult male healthy volunteers in comparison to Placebo using a crossover design.

A randomized, double blind, placebo controlled, cross over, two group, two period study to evaluate the efficacy of Sabeet® in cardio vascular and exercise performance in 20 adult male healthy volunteers.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006387
Enrollment
20
Registered
2015-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Sabeet®: One sachet daily with 150 ml of water for 2 weeks. Control Intervention1: Placebo: One sachet daily with 150 ml of water for a period of 2 weeks.

Sponsors

Sami labs Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Male healthy adult subjects ranging in age from 18 to 55 years (both inclusive) normotensive, physically active but not exercise trained. 2 Willingness to follow the protocol requirements as evidenced by written, informed consent. 3 Agree not to use any medication (prescription and over the counter), including vitamins and minerals, during or before the course of this study. 4 Subjects whose blood chemistries are within a normal range or not considered clinically significant if outside the normal range. 5 Non-smokers and non-alcoholics. 6 Willing to come for all follow-up visits.

Exclusion criteria

Exclusion criteria: 1 Any clinically significant medical history, medical finding or an ongoing medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol. 2 Significant abnormal findings as determined by baseline history, physical examination, vital signs (blood pressure, pulse rate, respiration rate, temperature) haematology, serum chemistry. 3 History of hypersensitivity reactions. 4 Participation in a clinical study during the preceding 90 days. 5 Any contraindication to blood sampling. 6 Blood or blood products donated in past 30 days prior to study supplement administration.

Design outcomes

Primary

MeasureTime frame
1 Standing blood pressure 2 Heart rate 3 Stroke volume and cardiac output 4 VO2 max by Cooper test 5 Time to exhaustion (cycling) 6 12-lead electrocardiogram 7 Gas exchange analysisTimepoint: 1 Standing blood pressure(Visit 2,Visit 3,Visit 4 & Visit 5) 2 Heart rate(Visit 2,Visit 3,Visit 4 & Visit 5) 3 Stroke volume and cardiac output(Visit 2,Visit 3,Visit 4 & Visit 5) 4 VO2 max by Cooper test(Visit 2,Visit 3,Visit 4 & Visit 5) 5 Time to exhaustion (cycling)(Visit 2,Visit 3,Visit 4 & Visit 5) 6 12-lead electrocardiogram(Visit 1,Visit 2,Visit 3,Visit 4 & Visit 5) 7 Gas exchange analysis(Visit 2,Visit 3,Visit 4 & Visit 5)

Secondary

MeasureTime frame
1 ESR and Hs-CRP 2 Plasma nitric oxide (NO)levels 3 Lactate dehydrogenase 4 Haematology, kidney and liver function testsTimepoint: 1 ESR and Hs-CRP (Visit 2,Visit 3,Visit 4 & Visit 5) 2 Plasma nitric oxide (NO)levels(Visit 2,Visit 3,Visit 4 & Visit 5) 3 Lactate dehydrogenase(Visit 2,Visit 3,Visit 4 & Visit 5) 4 Haematology, kidney and liver function tests(Visit 2,Visit 3,Visit 4 & Visit 5)

Countries

India

Contacts

Public ContactDr Deepa Subramanian

ClinWorld Private Limited

suresh@clinworld.org08028397973

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026